Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs Supplies DNA Sample Prep Reagents to Sanger Institute

Premium

New England Biolabs said last week that it will supply next-generation sequencing library construction reagents to the Wellcome Trust Sanger Institute.

New England Biolabs, based in Ipswich, Mass., will supply the Sanger Institute with NEBNext DNA Sample Prep Reagent Sets, which contain enzymes and buffers that are suited for preparing next-generation sequencing samples and expression libraries.

Reagents are available for each step of library construction workflow and are compatible with the Illumina GAII, Roche/454 GS FLX Titanium, and Life Technologies SOLiD 3 platforms.

"We are extremely pleased that the Wellcome Trust Sanger Institute, as a world-leading genome center, has determined that our reagents meet their high standards," Peter Nathan, director of global business development at New England Biolabs, said in a statement.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.